
Modern Diagnostic & Research Centre IPO Listing at 10.56% Premium at ₹99.50 Per Share
Posted by : sachet | Wed Jan 07 2026

Modern Diagnostic & Research Centre IPO listing: The Modern Diagnostic & Research Centre IPO was subscribed 376.90 times at the time of its closing. In this subscription, qualified institutional buyers (QIBs) received 193.51 times, and non-institutional investors (NIIs) received 702.08 times. The retail quota of the issue was subscribed to 33.26%. Before delving deeper into the topic, go through the details of the Modern Diagnostic & Research Centre IPO.
Modern Diagnostic & Research Centre IPO
It is a bookbuilding IPO of ₹36.89 crore, an entirely fresh issue of 0.41 crore shares. The issue will be listed on BSE and SME on its tentative listing date, 7th January 2026. The Modern Diagnostic & Research Centre IPO date is fixed between 31st December 2025 and 2nd January 2026. The face value of Modern Diagnostic & Research Centre shares stands at ₹10 per share, and the IPO Issue price band is set at ₹85 to ₹90 per share
| IPO Allotment Date | 5th January 2026 |
| IPO Open Date | 31st December 2025 |
| IPO Close Date | 6th January 2026 |
| Refund Initiation | 1st January 2026 |
| Issue Size | 40,99,200 shares(agg. up to ₹37 Cr) |
| Face Value | ₹10 per share |
| Lot Size | 1,600 Shares |
| Issue Price | ₹85 to ₹90 per share |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Listing Date | 7th January 2026 |
Modern Diagnostic & Research Centre IPO Listing
On the BSE & SME platforms, Modern Diagnostic & Research Centre shares are listed at ₹99.50 per share, reflecting a 10.56% premium to the issue price of ₹90.00 per share.
About the Modern Diagnostic & Research Centre IPO
Modern Diagnostic & Research Centre was established in 2016. Modern Diagnostic & Modern Diagnostic & Research Centre was established in 1985. Modern Diagnostic & Research Centre Limited (MDRC) is a diagnostic chain in India, offering a comprehensive range of pathology and radiology services. The company provides reliable diagnostic tests, home specimen collection, online reports, and customised test packages for institutional customers and patients, tailored to their specific needs. The company operates 21 centres (18 labs, three diagnostic centres) across eight states, offering diagnostic services such as ultrasound, CT, MRI, X-ray, ECG, PFT, and specialised labs for heart and neuro care. The company has been providing services such as Pathology, Radiology and Home sample collection.
Modern Diagnostic & Research Centre Limited Financials
The company’s financial analysis is essential before applying for Modern Diagnostic & Research Centre Limited’s IPO. Refer to the table to learn about Vidya Wires Limited’s financial information.
| Year Ended | 30th June 2025 (in cr.) | 31st March 2025 (in cr.) | 31st March 2024 | 31st March 2023 |
| Assets | 77.86 | 64.57 | 49.49 | 36.54 |
| Revenue | 22.67 | 78.80 | 68.67 | 56.61 |
| Profit After Tax | 3.00 | 8.97 | 5.79 | -5.73 |
| EBITDA | 5.86 | 17.96 | 11.05 | -0.99 |
| Net Worth | 23.72 | 20.73 | 11.76 | 5.96 |
| Reserves and Surplus | 12.72 | 9.73 | 10.76 | 4.96 |
| Total Borrowings | 30.38 | 22.09 | 20.46 | 15.31 |
Explanation
Modern Diagnostic & Research Centre Limited’s revenue increased by 15% from ₹68.67 crores in March 2024 to ₹78.80 crores in March 2025. Moreover, the company’s PAT increased by 55% from ₹5.79 crores in March 2024 to ₹8.97 crores in March 2025.
Recent Articles
Best Penny Stocks for Long Term in India | Penny Stocks in 2025
Berger Paints Q1 Results FY26: Q1 PAT Narrows 11.01% to ₹314.63 Crore; Revenue Surged 3.55% YoY
Tega Industries Q1 Results FY26: Q1 PAT Falls 3.83% to ₹35.34 Crore; Revenue Jumps 4.74% YoY
Alembic Pharmaceuticals Q1 Results FY26: Q1 PAT Soars 14.60% to ₹154.38 Crore; Revenue Up 9.54% YoY
Related Posts
Galaxy Agrico Q3 Results 2026 Highlights: Net Profit Surged by 500.00% & Revenue was flat at ₹1.00 Cr YoY
Amagi Media Labs IPO GMP & Review: Apply or Avoid?
INDO SMC IPO GMP & Review: Apply or Avoid?
Premier Energies Q3 Results FY26: Q3 PAT Flat at ₹0.00 Crore; Revenue Flat at ₹0.00 Crore YoY
GM Breweries Q3 Results 2026 Highlights: Net Profit Surged by 90.00% & Revenue Up 21.00% YoY

